Tissue Repair & HealingModerate Evidence

Ara-290 Peptide Therapy

Benefits, Side Effects, Cost & Protocols

Ara-290 peptide molecular structure diagram from PubChem

ARA-290 (cibinetide) is an 11-amino acid peptide derived from erythropoietin (EPO) that targets the innate repair receptor without hematopoietic side effects. It has been studied for neuropathy, tissue repair, and chronic inflammatory conditions in multiple human clinical trials.

ByChris Riley(CFA)&Alex Evans, PharmD, MBA(PharmD, MBA)|Updated May 19, 2026

Clinically Reviewed

Reviewed by Alex Evans, PharmD, MBA · Updated May 2026

Evidence-Based

Sourced from FDA, PubMed & ClinicalTrials.gov · View sources

FDA Status

Research Only Not currently approved for human use in the US. Available as a research compound. Not eligible for compounding.

Evidence

Moderate Evidence

Who Is Ara-290 Best For?

Neuropathic pain researchTissue repairNerve protectionLimited human trials or strong preclinical

How Ara-290 Works

Selectively activates the innate repair receptor (IRR) for tissue-protective effects without erythropoietic activity.

Ara-290 FAQ

What is ARA-290?

ARA-290 is a peptide derived from erythropoietin (EPO) researched for tissue repair and neuropathic pain applications without the blood-stimulating effects of EPO.

How does ARA-290 work?

Selectively activates the innate repair receptor (IRR) for tissue-protective effects without erythropoietic activity.

Is ARA-290 legal to buy?

ARA-290 is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.

Where can I buy ARA-290?

ARA-290 is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.

What category does ARA-290 belong to?

ARA-290 is primarily classified as a tissue repair & healing peptide. Peptides studied for their potential in wound healing, tendon/ligament repair, gut healing, and general tissue regeneration.

What are the research benefits of ARA-290?

ARA-290 has been studied for: Neuropathic pain research, Tissue repair, Nerve protection. Neuropathic pain/repair research peptide.

Key Studies

60 total on PubMed30 human trials

Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study

Heij L, Niesters M, Swartjes M et al

Mol Med · Mol MedPhase 2

ARA 290 safely reduced small fiber neuropathy symptoms and improved pain and physical functioning versus placebo.

ARA 290 safely reduced small fiber neuropathy symptoms and improved pain and physical functioning versus placebo

ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes

Brines M, Dunne AN, van Velzen M et al

Mol Med · Mol MedPhase 2

28 days treatment plus 28 days follow-up

ARA 290 improved hemoglobin A1c, lipid profiles, neuropathic symptoms, and corneal nerve fiber density in type 2 diabetes

ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density

Dahan A, Dunne A, Swartjes M et al

Mol Med · Mol MedRCT

ARA 290 significantly improved neuropathic symptoms and increased corneal nerve fiber density in sarcoidosis patients

Managing fatigue in sarcoidosis - A systematic review of the evidence

Chron Respir Dis · Chron Respir Dis

Ara-290 Compound Data

Molecular Formula

C51H84N16O21

Molecular Weight

1257.3 g/mol

IUPAC Name

(4S)-5-[[(1S)-4-amino-1-[[(1S)-1-[[(1S)-1-[[(1S)-1-[[(1S)-2-[[(1S)-1-[[(1S)-3-amino-1-[[(1S)-2-[[(1S)-1-carboxy-2-hydroxy-ethyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]carbamoyl]-3-oxo-propyl]carbamoyl]-3-methyl-butyl]amino]-1-methyl-2-oxo-ethyl]carbamoyl]-4-guanidino-butyl]carbamoyl]-3-carboxy-propyl]carbamoyl]-3-methyl-butyl]carbamoyl]-4-oxo-butyl]amino]-5-oxo-4-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid

View full compound on PubChem

Ara-290 News

The Power Of Peptides - Injuries And Tissue Repair - The Steeple Times

The Steeple Times · 4 months ago

ARA-290: Cytoprotection, Neuroimmune Signaling, and Systems-Level Regulation - Addis Insight

Addis Insight · 1 month ago

Non-hematopoietic roles of erythropoietin in inflammation and metabolic disorders - Frontiers

Frontiers · 10 months ago

Beyond perfusion: a review of peptide radiopharmaceuticals for cardiovascular imaging - Nature

Nature · 5 months ago

Unauthorized injectable peptides and their potential serious health risks - College of Physicians & Surgeons of Alberta | CPSA

College of Physicians & Surgeons of Alberta | CPSA · 1 month ago

News aggregated via Google News. Inclusion does not imply endorsement.

Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. Peptide therapies have not been evaluated by the FDA for most listed indications.All prices shown are estimates based on publicly available data and may not reflect current pricing — providers and brands set their own prices and can change them at any time. Always verify pricing directly with the provider before purchasing. Consult a licensed healthcare provider before starting any peptide protocol.

Ready to explore Ara-290 with a provider?

Take our 2-minute quiz to get matched with a board-certified provider specializing in Ara-290.

Take the Quiz →